ClinicalTrials.gg
RecruitingNCT06416371Updated Mar 4, 2026

Retinal Vessel Leakage in Cerebral Small Vessel Disease

An observational study in Cerebral Small Vessel Diseases, Lacunar Stroke and Vascular Dementia, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Primary conditionStroke, LacunarRegistry: Cerebral Small Vessel DiseasesReclassifiedWhy we changed it
Registry
Cerebral Small Vessel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stroke, Lacunar
Why
  1. The study's listed conditions name Stroke, Lacunar, a narrower term within Cerebral Small Vessel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Edinburgh · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are:

  • Does retinal vessel leakage occur in cerebral small vessel disease?
  • If it does, is the severity of retinal vessel leakage similar to the severity of cerebral small vessel disease generally?

Participants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels.

Participants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.

Read the detailed description

Cerebral small vessel disease (SVD) is a common cause of stroke and dementia. The molecular causes are unclear, limiting new therapies. Breakdown of the blood-brain barrier (BBB) is characteristic and may damage brain tissue. However, specialist MRI scans to measure BBB breakdown are expensive and time-consuming.

In contrast, measuring leakage from retinal blood vessels is relatively simple. The blood-retina barrier is very similar to the BBB, and SVD is likely to damage retinal and brain blood vessels in the same way. If so, then retinal angiography could be used to study SVD pathogenesis and measure the effect of new treatments with much greater resolution and lower cost than MRI.

We have three aims:

  1. Test the feasibility of fluorescein angiography in people with SVD
  2. Discover if retinal vessel leakage occurs people with SVD
  3. Discover whether the severity of retinal vessel leakage is associated with clinical features of SVD

We will recruit participants from a well-established cohort of people with SVD - the Mild Stroke Study 3 (MSS3).

02

Conditions studied

  • Cerebral Small Vessel Diseases
  • Lacunar Stroke
  • Vascular Dementia

Browse trials for

03

In context

Stroke, Lacunar Reclassified

21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.

Browse Stroke, Lacunar studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.

Compared within Stroke, Lacunar, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cerebral Small Vessel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults >18 years old with mild ischaemic stroke with a modified Rankin scale (mRS) greater or equal to 2 at recruitment presenting to Edinburgh/Lothian stroke services.

For details see Clancy, et al (2021) Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. European Stroke Journal 6:81-88. https://doi.org/10.1177/2396987320929617

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Membership in the Mild Stroke Study 3 cohort
  • Contrast enhanced MRI within 12 months
  • Clear optical media in both eyes, as assessed by study investigator
  • Best corrected visual acuity (near vision) ≥N36

Exclusion criteria

Exclusion Criteria:

  • Any condition known to cause retinal leakage (i.e., worse than background diabetic retinopathy, retinal vein occlusion, active uveitis, wet age-related macular degeneration, malignant hypertension)
  • Previous treatment for retinal leakage (retinal laser, intravitreal anti-VEGF)
  • Recent eye surgery
  • Shallow anterior chambers as assessed by torch test
  • Pregnancy, renal failure
  • Severe dementia
  • Known allergy to fluorescein
  • History of allergy such as food or drug induced urticaria or history of bronchial asthma
  • Any other severe or acute medical or psychiatric conditions
  • Inability to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testFundus fluorescein angiography, with ultrawide field retinal imaging

    Intravenous injection of sodium fluorescein for angiography of retinal blood vessels

06

What researchers measure

Primary outcomes

  1. Retinal vessel leakage by automated segmentation

    The presence and severity of retinal vessel leakage will be measured for each eye in terms of change in pixel brightness over the duration of the angiogram.

    Time frame: within one angiogram

  2. Retinal vessel leakage by manual grading

    The presence and severity of retinal vessel leakage will be measured using an manual ordinal grading scale

    Time frame: within one angiogram

Secondary outcomes

  1. Baseline blood-brain barrier breakdown

    BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium

    Time frame: Within one MRI scan

  2. White matter hyperintensity (WMH) volume adjusted for brain volume

    This is measured from the most recent structural MRI scan

    Time frame: Within one MRI scan

  3. Change in white matter hyperintensity (WMH) volume adjusted for brain volume

    This is measured by comparing the most recent structural MRI scan with the baseline structural MRI scan

    Time frame: Difference in MRI scans up to 5 years prior

  4. Fazekas score

    This is measured from the most recent structural MRI scan

    Time frame: Within one MRI scan

  5. Change in Fazekas score

    This is measured by comparing the most recent structural MRI scan with the baseline structural MRI scan

    Time frame: Difference in MRI scans up to 5 years prior

  6. Baseline average leakage in white matter hyperintensities

    BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium

    Time frame: Within one MRI scan

  7. Baseline average leakage in deep grey matter

    BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium

    Time frame: Within one MRI scan

  8. Baseline number of leakage hotspots

    BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium

    Time frame: Within one MRI scan

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Clancy U, Garcia DJ, Stringer MS, Thrippleton MJ, Valdes-Hernandez MC, Wiseman S, Hamilton OK, Chappell FM, Brown R, Blair GW, Hewins W, Sleight E, Ballerini L, Bastin ME, Maniega SM, MacGillivray T, Hetherington K, Hamid C, Arteaga C, Morgan AG, Manning C, Backhouse E, Hamilton I, Job D, Marshall I, Doubal FN, Wardlaw JM. Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. Eur Stroke J. 2021 Mar;6(1):81-88. doi: 10.1177/2396987320929617. Epub 2020 Jun 5. PubMed 33817338 ↗
  • MacCormick IJ, Maude RJ, Beare NA, Borooah S, Glover S, Parry D, Leach S, Molyneux ME, Dhillon B, Lewallen S, Harding SP. Grading fluorescein angiograms in malarial retinopathy. Malar J. 2015 Sep 24;14:367. doi: 10.1186/s12936-015-0897-7. PubMed 26403288 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Feb 2029, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
May 16, 2024
StartActual
Jan 13, 2025
Primary completionEst.
Feb 15, 2029
CompletionEst.
Feb 15, 2029
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06416371
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Jan 13, 2025
Primary completion
Feb 15, 2029 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion